Aclaris therapeutics announces top-line results from 4-week phase 2b trial of ati-1777 for mild to severe atopic dermatitis

- ati-1777 2% bid achieved a statistically significant result in the primary efficacy endpoint at week 4 - - minimal systemic exposure supports “soft” topical jak inhibitor approach - - ati-1777 was well tolerated - wayne, pa., jan. 10, 2024 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced top-line results from its phase 2b study of ati-1777, an investigational topical “soft” jak 1/3 inhibitor, in patients with mild to severe atopic dermatitis (ad) (ati-1777-ad-202; nct05432596).
ACRS Ratings Summary
ACRS Quant Ranking